# Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

> **NCT06918132** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 60 (estimated)

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Stage IB Lung Cancer AJCC v8
- Stage II Lung Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Cemiplimab
- **BIOLOGICAL:** Fianlimab
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Surgical Procedure
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06918132
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-29
- **Primary completion:** 2027-04-29
- **Final completion:** 2027-04-29
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06918132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06918132, "Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06918132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*